Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) closed the day trading at $47.26 up 0.33% from the previous closing price of $47.11. In other words, the price has increased by $0.33 from its previous closing price. On the day, 1.44 million shares were traded. SUPN stock price reached its highest trading level at $47.69 during the session, while it also had its lowest trading level at $45.63.
Ratios:
For a better understanding of SUPN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.43 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.26. For the most recent quarter (mrq), Quick Ratio is recorded 1.56 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On July 30, 2025, Cantor Fitzgerald Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $42.
Cantor Fitzgerald Downgraded its Overweight to Neutral on February 19, 2025, whereas the target price for the stock was revised from $57 to $36.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 09 ’25 when Khattar Jack A. sold 59,900 shares for $50.57 per share. The transaction valued at 3,029,336 led to the insider holds 1,206,578 shares of the business.
NEWHALL CHARLES W III sold 25,000 shares of SUPN for $1,269,234 on Oct 09 ’25. The Director now owns 104,644 shares after completing the transaction at $50.77 per share. On Oct 09 ’25, another insider, JACK A. KHATTAR, who serves as the Director of the company, bought 59,900 shares for $48.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SUPN now has a Market Capitalization of 2699736576 and an Enterprise Value of 2449998848. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.89 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 3.595 whereas that against EBITDA is 61.567.
Stock Price History:
The Beta on a monthly basis for SUPN is 0.72, which has changed by 0.2871585 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, SUPN has reached a high of $57.65, while it has fallen to a 52-week low of $29.16. The 50-Day Moving Average of the stock is -2.71%, while the 200-Day Moving Average is calculated to be 24.82%.
Shares Statistics:
Over the past 3-months, SUPN traded about 882.05K shares per day on average, while over the past 10 days, SUPN traded about 1329670 shares per day. A total of 57.12M shares are outstanding, with a floating share count of 52.83M. Insiders hold about 5.79% of the company’s shares, while institutions hold 104.82% stake in the company. Shares short for SUPN as of 1760486400 were 4954765 with a Short Ratio of 5.62, compared to 1757894400 on 5019809. Therefore, it implies a Short% of Shares Outstanding of 4954765 and a Short% of Float of 12.590000000000002.
Earnings Estimates
. The current rating of Supernus Pharmaceuticals Inc (SUPN) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.51, with high estimates of $0.52 and low estimates of $0.5.
Analysts are recommending an EPS of between $5.95 and $5.95 for the fiscal current year, implying an average EPS of $5.95. EPS for the following year is $4.3, with 3.0 analysts recommending between $6.04 and $3.26.
Revenue Estimates
6 analysts predict $195.48M in revenue for. The current quarter. It ranges from a high estimate of $202.7M to a low estimate of $184.8M. As of. The current estimate, Supernus Pharmaceuticals Inc’s year-ago sales were $174.16MFor the next quarter, 6 analysts are estimating revenue of $192.18M. There is a high estimate of $203.7M for the next quarter, whereas the lowest estimate is $182.5M.
A total of 6 analysts have provided revenue estimates for SUPN’s current fiscal year. The highest revenue estimate was $710M, while the lowest revenue estimate was $692.2M, resulting in an average revenue estimate of $702.84M. In the same quarter a year ago, actual revenue was $661.82MBased on 6 analysts’ estimates, the company’s revenue will be $867.02M in the next fiscal year. The high estimate is $902.5M and the low estimate is $824.1M.
